New Triple-Threat attack on blood cancer tested in patients
NCT ID NCT04624633
Summary
This study is testing whether a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—can control the growth of chronic lymphocytic leukemia (CLL). It is enrolling adults with CLL, including those whose cancer has come back after treatment and those who have never been treated. The goal is to see if using these drugs together is more effective at putting the cancer into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.